Cerenome (CNSY) Investor update summary

Strategic context and market opportunity

• CNS cancers remain a major unmet need, with stagnant survival rates despite advances in oncology.

• The U.S. CNS cancer at-risk pool is estimated at 2 million, with 600,000 annual CNS workups and a total addressable diagnostic market of $2.7 billion for LM and $2.8 billion for broader CNS populations.

• The integrated approach combines diagnostics, therapeutics, and data analytics to address CNS cancer complexity.

Commercial progress and payer coverage

• Achieved commercial coverage for 158 million lives, surpassing the 2026 goal ahead of schedule and targeting 200 million by early 2027.

• Medicare enrollment is complete, with a published rate expected to be effective January 1, 2027, and Medicaid coverage progressing state by state.

• Billing infrastructure is operational, and claims submissions began this quarter, including for earlier tests.

Test adoption, menu expansion, and laboratory capacity

• On track for a 1,250 annualized test run rate in Q4 2026, with Q3 test volume up 41% over Q2.

• CNSide CSF Molecular Profile Test launches October 12, and breast cancer-focused CSF cellular biomarkers debut in November.

• Laboratory capacity expanded to support up to 50,000 tests annually, eliminating growth constraints.